Can Hepatitis C virus treatment be used as a prevention strategy? Additional model projections for Australia and elsewhere

Drug and Alcohol Dependence

Volumn 113, Issue 2-3, 2011, Pages 83-85

  Vickerman, Peter ^a,b   Martin, Natasha ^a,b   Hickman, Matthew ^b  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

HCV; IDU; Mathematical model; Treatment

Indexed keywords

PEGINTERFERON; RIBAVIRIN;

ANTIVIRAL THERAPY; AUSTRALIA; DRUG ABUSE; HEALTH CARE UTILIZATION; HEPATITIS C; INFECTION PREVENTION; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; METHADONE TREATMENT; NOTE; PREVALENCE; PRIORITY JOURNAL;

ANTIVIRAL AGENTS; AUSTRALIA; HEPATITIS C; HUMANS; INTERFERON ALFA-2A; METHADONE; MODELS, STATISTICAL; OPIATE SUBSTITUTION TREATMENT; POLYETHYLENE GLYCOLS; PREVALENCE; PRIMARY PREVENTION; RIBAVIRIN; SUBSTANCE ABUSE, INTRAVENOUS;

HEPATITIS C VIRUS;

EID: 78651469588     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2010.08.001     Document Type: Note

References (15)

1. Aitken C.K., Lewis J., Tracy S.L., Spelman T., Bowden D.S., Bharadwaj M., Drummer H., Hellard M. High incidence of hepatitis C virus reinfection in a cohort of injecting drug users. Hepatology 2008, 48:1746-1752.
2. Baggaley R.F., Ferguson N.M., Garnett G.P. The epidemiological impact of antiretroviral use predicted by mathematical models: a review. Emerg. Themes Epidemiol. 2005, 2:9.
3. Degenhardt L., Mathers B., Vickerman P., Rhodes T., Latkin C., Hickman M. Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed. Lancet 2010, 376:285-301.
4. Des Jarlais D.C., Perlis T., Arasteh K., Torian L.V., Hagan H., Beatrice S., Smith L., Wethers J., Milliken J., Mildvan D., Yancovitz S., Friedman S.R. Reductions in hepatitis C virus and HIV infections among injecting drug users in New York City, 1990-2001. AIDS 2005, 19(Suppl. 3):S20-S25.
5. Granich R.M., Gilks C.F., Dye C., De Cock K.M., Williams B.G. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009, 373:48-57.
6. Hellard M., Sacks-Davis R., Gold J. Hepatitis C treatment for injection drug users: a review of the available evidence. Clin. Infect. Dis. 2009, 49:561-573.
7. Malta M., Strathdee S.A., Magnanini M.F., Bastos F.I. Adherence to antiretroviral therapy for human immunodeficiency virus/acquired immune deficiency syndrome among drug users: a systematic review. Addiction 2008, 103:1242-1257.
8. McHutchison J.G., Manns M.P., Muir A.J., Terrault N.A., Jacobson I.M., Afdhal N.H., Heathcote E.J., Zeuzem S., Reesink H.W., Garg J., Bsharat M., George S., Kauffman R.S., Adda N., Di Bisceglie A.M. Telaprevir for previously treated chronic HCV infection. N. Engl. J. Med. 2010, 362:1292-1303.
9. Micallef J.M., Kaldor J., Dore G.J. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J. Viral Hepatitis 2006, 13:34-41.
10. Miller E.R., Hellard M.E., Bowden S., Bharadwaj M., Aitken C.K. Markers and risk factors for HCV, HBV and HIV in a network of injecting drug users in Melbourne, Australia. J. Infect. 2009, 58:375-382.
11. National Centre in HIV Epidemiology and Clinical Research Hepatitis C Virus Projections Working Group: Estimates and Projections of the Hepatitis C Virus Epidemic in Australia 2006 2006, The University of New South Wales, Sydney.
12. Palmateer N., Kimber J., Hickman M., Hutchinson S., Rhodes T., Goldberg D. Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews. Addiction 2010, 105:844-859.
13. Sterne J.A., Hernan M.A., Ledergerber B., Tilling K., Weber R., Sendi P., Rickenbach M., Robins J.M., Egger M. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet 2005, 366:378-384.
14. van Den Berg C., Smit C., Van Brussel G., Coutinho R.A., Prins M. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam cohort studies among drug users. Addiction 2007, 102:1454-1462.
15. Zeiler I., Langlands T., Murray J.M., Ritter A. Optimal targeting of Hepatitis C virus treatment among injecting drug users to those not enrolled in methadone maintenance programs. Drug Alcohol Depend. 2010, 110:228-233.